On 12 and 13 April 2018, at the Department of Food and Drug of the University of Parma, the two days course “Quality by Design in Pharmaceutical Development” will take place. Theory and case studies”.
PlumeStars participated at the 2nd International Awareness Session – The EU medicines regulatory system and the European Medicines Agency which was held on 8 and 9 March in London (UK).
On Friday, December 15th, the one-day workshop on “Fixed dose combinations of drugs: clinical aspects, formulations and regulatory” took place in Milan at the Department of Pharmaceutical Sciences,UNIMI .
PlumeStars attended the 2017 AAPS Annual Meeting & Exposition in San Diego presenting a poster on the last orphan medicine getting the EMA and FDA orphan designation. The orphan medicine presented was the powder of thalidomide prepared for both the oral and nasal administration.
On Friday, November 10, at the Aula Magna of the University of Parma (Via Università 12), the meeting “Malignant pleural mesothelioma: preclinical and clinical research” will take place.
PlumeStars participated at the 4th International Meeting on “Inhaled therapies for tubercolosis and other infectious disease: products, technologies and procedures for efficiently treating pulmonary diseases” which was held on 16 and 17 October in Durham (NC).
This meeting focuses on tuberculosis and intends from TB therapy to translate products, technologies and procedures for efficiently treating the pulmonary infective diseases.
PlumeStars and Biopharmanet-Tec will attend together with the company Lisapharma spa The Eight World Congress of Orphan Medicines, in Barcelona on 14 and 15 November 2017.
The Congress brings together companies, start-ups and stakeholders in the field of orphan diseases and rare diseases.
Cardiovascular diseases, such as myocardial infarct and heart failure, represent a societal burden, accounting for more than 30% of deaths globally and spending yearly ~190 billion € in European healthcare. The chronic treatment of patients leads only to short-term benefits, since the conventional therapies show several weak points.
On Friday, July 21, 2017, a Framework Agreement has been signed between the University of Parma and PlumeStars s.r.l. concerning a didactic and scientific collaboration between the Food and Drug Department and the start up PlumeStars.
On June 8th, the 11th edition of the Innovation & Match 2017 was held, the intermediation event with bilateral meetings between companies, research centers and universities, organized by ASTER and Emilia-Romagna Enterprise Europe Network partners of the SIMPLER consortium.
The event took place within R2B – Research to Business 2017, the 12th edition of the International Industrial Research Exhibition, promoted by the Emilia-Romagna Region, Bologna Fiere, ASTER and SMAU.